Key result
High-sensitivity cardiac troponin testing may allow for more refined risk stratification and individualized care in patients with chronic cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
High-sensitivity cardiac troponin assays may have utility beyond acute settings for risk stratification and individualized care in chronic conditions like coronary artery disease, heart failure, and diabetes.
The cardiac troponins are important cardiovascular biomarkers for myocardial necrosis and are measured in thousands of patients daily. In parallel with the widespread adoption of troponin testing for the diagnosis of myocardial infarction during the last two decades, the analytical sensitivity of assays has progressively improved, which has allowed the identification of more acute coronary syndrome patients at risk of future cardiac events. In addition, using novel high-sensitivity assays, circulating troponin can be observed not only in acute settings, but also in many patients suffering from chronic diseases such as coronary artery disease, heart failure and diabetes. We believe that these findings provide a compelling case for exploring whether troponin levels may be a useful tool for guiding clinical decision-making directly in the management of some of these chronic conditions. Sampling of troponin in such patient populations may allow for more refined risk stratification and, importantly, help clinicians individualize care beyond what is currently possible.
No takes yet. Share an insight, caveat, or question.
Hallén et al. (2010) conducted a review in Cardiovascular disease. High-sensitivity cardiac troponin testing was evaluated. High-sensitivity cardiac troponin testing may allow for more refined risk stratification and individualized care in patients with chronic cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: